Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC

Autor: John W. G. van Putten, Harry J.M. Groen, Floris M Wachters, H. Marike Boezen
Přispěvatelé: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Research Institute for Asthma and COPD (GRIAC)
Jazyk: angličtina
Rok vydání: 2004
Předmět:
Oncology
Male
Cancer Research
Lung Neoplasms
medicine.medical_treatment
carcinoma
PACLITAXEL
Gastroenterology
SINGLE-AGENT
chemistry.chemical_compound
IFOSFAMIDE
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
docetaxel
Infusions
Intravenous
second-line chemotherapy
clinical trial
Middle Aged
phase II
Prognosis
Treatment Outcome
Docetaxel
carboplatin
Female
Taxoids
CLINICAL-TRIALS
medicine.drug
Epirubicin
Pulmonary and Respiratory Medicine
Adult
medicine.medical_specialty
Maximum Tolerated Dose
CELL LUNG-CANCER
CONTAINING CHEMOTHERAPY
VINORELBINE
Risk Assessment
Drug Administration Schedule
CISPLATIN
Internal medicine
medicine
Humans
COMBINATION
neoplasms
Aged
Neoplasm Staging
Probability
Proportional Hazards Models
Salvage Therapy
Chemotherapy
Performance status
Dose-Response Relationship
Drug
business.industry
medicine.disease
Survival Analysis
Gemcitabine
Carboplatin
Logistic Models
non-small-cell lung
chemistry
GEMCITABINE
Liver function
business
Febrile neutropenia
Zdroj: Lung Cancer, 45(2), 255-262. ELSEVIER IRELAND LTD
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2004.02.006
Popis: Aim of this study was to evaluate activity and toxicity of docetaxel and carboplatin as second-tine treatment in advanced non-small-cell lung cancer (NSCLC) patients who failed or relapsed after previous chemotherapy. Patients had to have unresectable stage IIIb or IV NSCLC, previous chemotherapy, a performance status less than or equal to2, a normal bone marrow reserve, and an adequate renal and liver function. Treatment consisted of docetaxel 75 mg/m(2) and carboplatin AUC 6 mg/ml min administered every 3 weeks for a maximum of 5 cycles. Fifty-seven patients with a median age of 57 years were included. Prior treatment consisted of gemcitabine atone (n = 2) or gemcitabine in combination with cisplatin (n = 26) or epirubicin (n = 29). Median number of cycles for carboplatin and docetaxel was 4. Granulocytopenia and thrombocytopenia common toxicity criteria (CTC) grades 3 and 4 occurred in 79 and 30% of patients, respectively. Febrile neutropenia, occurred in eight patients (14%), of whom two patients died. Fatigue grades 2 and 3 occurred in 42% of patients. Other non-haematotogical toxicity was mild. Tumour response rate was 37%, irrespective of the previous regimen. Median survival was 31 weeks, 1-year survival was 32%. In conclusion, the combination of docetaxel and carboplatin is active as second-tine treatment in platinum and non-platinum pre-treated patients. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: